Abdelrahim, M.; Esmail, A.; Al-Najjar, E.; Khasawneh, B.; Umoru, G.; Abdelrahim, W.; Abboud, K.; Ajewole, V.B.
Safety and Efficacy of Regorafenib and 5-Fluorouracil Combination Therapy in Refractory Metastatic Colorectal Cancer After Third-Line Treatment: An Institutional Experience. Biomedicines 2025, 13, 1151.
https://doi.org/10.3390/biomedicines13051151
AMA Style
Abdelrahim M, Esmail A, Al-Najjar E, Khasawneh B, Umoru G, Abdelrahim W, Abboud K, Ajewole VB.
Safety and Efficacy of Regorafenib and 5-Fluorouracil Combination Therapy in Refractory Metastatic Colorectal Cancer After Third-Line Treatment: An Institutional Experience. Biomedicines. 2025; 13(5):1151.
https://doi.org/10.3390/biomedicines13051151
Chicago/Turabian Style
Abdelrahim, Maen, Abdullah Esmail, Ebtesam Al-Najjar, Bayan Khasawneh, Godsfavour Umoru, Waseem Abdelrahim, Karen Abboud, and Veronica B. Ajewole.
2025. "Safety and Efficacy of Regorafenib and 5-Fluorouracil Combination Therapy in Refractory Metastatic Colorectal Cancer After Third-Line Treatment: An Institutional Experience" Biomedicines 13, no. 5: 1151.
https://doi.org/10.3390/biomedicines13051151
APA Style
Abdelrahim, M., Esmail, A., Al-Najjar, E., Khasawneh, B., Umoru, G., Abdelrahim, W., Abboud, K., & Ajewole, V. B.
(2025). Safety and Efficacy of Regorafenib and 5-Fluorouracil Combination Therapy in Refractory Metastatic Colorectal Cancer After Third-Line Treatment: An Institutional Experience. Biomedicines, 13(5), 1151.
https://doi.org/10.3390/biomedicines13051151
